Parkinson disease (PD) is, without doubt, a burden on modern society as the prevalence increases significantly with age. Owing to this growing number of PD cases, it is more critical than ever to understand the pathogenic mechanisms underlying PD to identify therapeutic targets. The discovery of genetic mutations associated with PD and parkinsonism paves the way toward this goal. Even though, familial forms of the disease represent the minority of PD cases and some forms are so rare that there are only a few affected families, the research on the associated genes is invaluable. Recent additions to PARK mutations are those in PARK15 that encodes the F-box protein O-type 7 (FBXO7). In this review, we highlight the recent research on FBXO7, which advances our knowledge of the etiopathological pathways and fills unexpected gaps therein, justifying the dedicated study of rare variants of PD.
Parkinson's disease (PD) is a devastating diagnosis as there is currently no cure for this movement disorder. While the treatment available to date alleviates the symptoms to a great extent (Oertel and Schulz 2016) , the disease also causes significant psychological and economic burden on patients and caring families. With a steadily rising prevalence of PD in the population aged 50 and older (Pringsheim et al. 2014) , research is more important than ever.
Most cases of PD/parkinsonism are sporadic and characterized by the slow death of selective populations of neurons. The loss of dopaminergic neurons in the substantia nigra pars compacta in particular and hence the loss of dopamine homeostasis in the striatum give rise to the cardinal signs of this movement disorder that include bradykinesia, resting tremor, postural instability, and rigidity. Among the 15% of patients that comprise familial cases, the discovery of genetic mutations launched a new era of PD research that allowed for a molecular approach in understanding the disease (Beilina and Cookson 2016; Hernandez et al. 2016) . The first genetic mutations identified in PD patients were found in PARK1/4, encoding a-synuclein (Polymeropoulos et al. 1997) . Genetic mutations in PARK8, encoding leucine-rich repeat kinase 2, are the most frequent in late-onset PD with varying frequencies depending on the population (Berg et al. 2005 ; Lesage et al. 2006; Ozelius et al. 2006) . Mutations in PARK2, encoding parkin, and in PARK6, encoding PTENinduced putative kinase 1 (PINK1), are most frequent in early-onset familial cases. According to recent metaanalyses, parkin and PINK1 mutations are found in more than 15% and 8% of early-onset PD patients, respectively (Kilarski et al. 2012) . The past decade revealed several additional genetic mutations that are associated with rare, atypical parkinsonism. While these mutations are found in only a few families, they appear to be of rather negligible relevance at first glance. With new genes emerging, however, novel genetic animal models together with more detailed molecular insight will be available. This will allow for a generalizable view of the etiology and pathogenesis of PD, and ultimately better strategies to develop therapies.
Almost two decades of research uncovered that several PARK genes functionally interact and act in common pathways that include mitochondrial quality control, oxidative stress response and protein degradation pathways (Scott et al. 2017) . Parkin together with PINK1 are known to regulate mitochondrial function (Pickrell and Youle 2015) , unveiling mitochondria as a central target in the search for a cure. PARK2 (parkin), PARK5 (UCH-L1), PARK15 (F-box protein O-type 7, FBXO7), which comprise components of the ubiquitin proteasome system (UPS), and together with a-synuclein, affect UPS functions, underscoring the importance of the UPS in the etiopathogenesis of PD (Walden and Muqit 2017) . In this short review, we will highlight recent findings on FBXO7, which accentuate that research of rare forms is beneficial and rewarding.
PARK15 syndrome
Autosomal-recessive mutations in PARK15 (FBXO7) were first identified in a genome-wide linkage analysis of families affected by a juvenile form of parkinsonism. (Shojaee et al. 2008) . A second report confirming the association of the PARK15 gene with atypical parkinsonism was published shortly thereafter (Di Fonzo et al. 2009) . This rare disorder, referred to as Parkinsonian-pyramidal syndrome, was originally described by Davison (1954) , followed by several case reports. These clinical descriptions and characterizations had emerged prior to the identification of any causative genetic mutations (Horowitz and Greenberg 1975; Nisipeanu et al. 1994; Remy et al. 1995; Rajendran et al. 2000; Kalita et al. 2003) . As of now, FBXO7 mutations and the novel a-synuclein G51D mutation have been implicated in Parkinsonian-pyramidal syndrome (Lesage et al. 2013) .
PARK15 patients display heterogenic phenotypes characterized by either a classic PD phenotype, pyramidal tract signs only, or by a combination of parkinsonism and pyramidal signs, which is true for the majority of the individuals. PARK15 patients show typical Parkinsonian features (bradykinesia, rigidity, resting tremor, and postural instability), in addition to spasticity, impaired fine movements and Babinski sign, which characterize pyramidal tract signs. PARK15 patients often show further signs including dystonia, dysphagia, dysarthria, cortical atrophy and/or cognitive decline (Shojaee et al. 2008; Di Fonzo et al. 2009; Gunduz et al. 2014; Yalcin-Cakmakli et al. 2014; Lohmann et al. 2015) . But also patients with typical ageat-onset and typical clinical symptoms of PD have been identified (Lohmann et al. 2015) .
Onset of disease in reported patients occurred in childhood (as young as 10 years), adolescence, or young adulthood (Shojaee et al. 2008; Di Fonzo et al. 2009; Gunduz et al. 2014; Yalcin-Cakmakli et al. 2014; Lohmann et al. 2015) . But also a family with onset in the 40s and 50s has been reported (Lohmann et al. 2015) . As to why the age-of-onset is so different in these patients is unknown. The genetic background, especially that of consanguineous families, may be a strong contributor to age-of-onset. MRI of the brain was unremarkable or showed mild general atrophy but no abnormalities of the basal ganglia (Shojaee et al. 2008; Di Fonzo et al. 2009; Gunduz et al. 2014; Yalcin-Cakmakli et al. 2014; Lohmann et al. 2015) . The pathological DaTSCAN-SPECT and normal IBZM-SPECT confirmed the diagnosis of a pre-synaptic dopaminergic deficit (Di Fonzo et al. 2009 ). All reported patients responded well to L-Dopa and dopamine receptor agonist therapy, but developed side effects at early stages of the therapy, including disabling dyskinesia (levodopa-induced dyskinesia), and even psychotic episodes, behavioral disturbances, and hallucinations (Shojaee et al. 2008; Di Fonzo et al. 2009; Gunduz et al. 2014; Yalcin-Cakmakli et al. 2014; Lohmann et al. 2015) , These aforementioned side effects occurred in patients with L-Dopa-responsive, idiopathic PD and also in a patient that presented with a pre-synaptic dopaminergic deficit.
No neuropathological reports are available. Therefore, the question of whether or not patients with PARK15 mutations suffer from Lewy-body-positive PD and whether their disease fulfills the criteria of an a-synucleinopathy pathologically cannot be answered.
FBXO7 gene, protein, and mutations
Human PARK15 translates into the 522 amino acid protein FBXO7 isoform 1. This isoform is expressed in various types of tissues including gray and white matter areas of the brain (Vingill et al. 2016) . Our recent study established a predominantly cytoplasmic localization of FBXO7 using an FBXO7 knockout tissue-validated antibody. ENSEMBL annotated transcript indicates two additional shorter isoforms with different N-termini , their expression profile and localization, however, remain to be determined.
FBXO7 (F-box only 7) was first identified in a yeast twohybrid screen using S-phase kinase-associated protein 1 (SKP1) as bait (Cenciarelli et al. 1999; Winston et al. 1999) . FBXO7 harbors an F-box domain and hence belongs to the family of F-box proteins, which are classified based on different domains and motifs: FBXLs, which contain leucinerich repeats, FBXWs that harbor a WD40 domain and FBXOs with no additional or other domains (Jin et al. 2004) .
With only few exceptions, F-box proteins are the interchangeable subunits of the SKP1/cullin-1/F-box protein (SCF) E3 complex.
In addition to SKP1, FBXO7 associates with cullin1 and RING-box protein 1 and forms a multimeric E3 ubiquitin ligase. Here, cullin1 and SKP1 constitute the core of the E3 ligase, RING-box protein 1 harbors the RING (really interesting new gene) domain that recruits the E2-ubiquitinconjugating enzyme bound to ubiquitin via a thioester bond, whereas FBXO7 acts as substrate-recruiting subunit. To ubiquitinate a substrate, the FBXO7-SCF complex brings the E2-ubiquitin-conjugate and the substrate in close proximity.
The FBXO7 protein contains different functional domains: At its N-terminus, FBXO7 contains an ubiquitin-related (UbR) domain, which mediates the interaction with the proteasome subunit proteasomal subunit A2 (PSMA2) (Vingill et al. 2016 ) and the interaction with parkin to regulate mitochondrial quality control (Burchell et al. 2013) . FBXO7 isoform 2 lacks the UbR domain and hence does not support any functions that are mediated by the interaction with PSMA2 or parkin. The interaction of FBXO7 with the cyclinD/CDK6 complex via the cyclin-dependent kinase 6 binding domain, is required for distinct aspects of cell cycle regulation (Laman 2006) . The FP (FBXO7/proteasomal inhibitor 31, PI31) domain facilitates the interaction with the proteasomal regulator 31 (Kirk et al. 2008 ). The eponymous F-box domain mediates the interaction of FBXO7 and SKP1 (Cenciarelli et al. 1999) . At its Cterminus, FBXO7 harbors a proline-rich region, which has been shown to be another site of interaction with the cell cycle-relevant protein hepatoma up-regulated protein and Cdk6 (Hsu et al. 2004; Kirk et al. 2008) . Taken together, these domains facilitate the specific interaction of FBXO7 with its binding partners and in particular with its target substrates.
As of now, the following FBXO7 mutations found in PARK15 patients have been described: an L34R missense mutation, a compound mutation comprising a T22M missense mutation together with a mutation at the internal splice site (IVS7+1G/T), the R378G missense mutation, and the R498X nonsense mutation (Shojaee et al. 2008; Di Fonzo et al. 2009; Gunduz et al. 2014; Yalcin-Cakmakli et al. 2014; Lohmann et al. 2015) . While L34R and T22M are located in the UbR domain, R378G lies adjacent to the F-box domain, and R498X disrupts the proline-rich region. The FBXO7 gene also displays various single-nucleotide polymorphisms (SNPs) and a recent study examined the cosegregation of PD and SNPs that generate the missense mutations Y52C and M115I. The results revealed significantly fewer individuals with PD that carry the G allele of the Y52C SNP (Chen et al. 2014) , suggesting a protective genotype. While this is an intriguing finding, the minor allelic frequency of the G allele in the control group is very low, which requires further validation with larger cohorts. In general, the search for biomarkers, which includes the identification of genetic variants that predispose for PD or favor certain manifestations of PD, are valuable for a more personalized treatment regimen. This applies to existing as well as to future treatments.
FBXO7 and mitochondrial clearance
Mitochondria are highly dynamic organelles and the adenosine triphosphate (ATP)-producing powerhouses of the cell. Fusion and fission events as well as the degradation of mitochondria referred to as mitophagy are crucial for maintaining a healthy pool of mitochondria. Mitochondrial damage and dysfunctions in the substantia nigra have been previously associated with sporadic PD in postmortem tissue and cell cultures derived from PD patients (Schapira et al. 1990; Keeney et al. 2006; Parker et al. 2008; Schapira 2008; Bose and Beal 2016) . In addition, magnetic resonance spectroscopy studies of PD patients underscored mitochondrial dysfunction in the brain (Rango et al. 2006; Henchcliffe and Beal 2008) . These observations supported the notion that aberrant mitochondrial functioning is a critical contributor to the pathological degeneration of neurons in PD.
The discoveries that parkin and PINK1 act together in mitophagy made it even more evident that a pathological mitochondria pathway is central to PD. The serine-threonine kinase PINK1 is a mitochondrially targeted protein, which undergoes rapid degradation owing to its processing at healthy mitochondria. Mitochondrial membrane depolarization as a consequence of dysfunction, however, leads to the stabilization of PINK1 and results in the exposed localization on mitochondria (Matsuda et al. 2010; Narendra et al. 2010) . Exposed PINK1 works as a signal that recruits the E3 ubiquitin ligase parkin to dysfunctional mitochondria. This results in the phosphorylation of parkin by PINK1, which in turn stimulates parkin's E3 ligase activity (Narendra et al. 2008; Vives-Bauza et al. 2010; Kondapalli et al. 2012; Shiba-Fukushima et al. 2012) . Successful mitophagy also requires the phosphorylation of ubiquitin. Here, phosphorylated ubiquitin stimulates parkin activity and triggers the recruitment of damaged mitochondria to the phagophore for subsequent mitophagy (Kane et al. 2014; Kazlauskaite et al. 2014; Koyano et al. 2014; Matsuda 2016) . Both mutated PINK1 and parkin are associated with morphologically and functionally abnormal mitochondria indicating that the proper clearance of damaged organelles fails (Henchcliffe and Beal 2008; Narendra et al. 2012) .
The signaling cascade resulting in mitophagy is even more complex and requires yet another PARK product: FBXO7. The study by Burchell and colleagues established that FBXO7 and parkin are novel interaction partners. In addition, they reported that FBXO7 is recruited to damaged mitochondria, induced by, e.g., the uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and that FBXO7 is required for a successful recruitment of parkin (Burchell et al. 2013) , Fig. 1 . The interaction is mediated by the UbR domain and the T22M mutation, located in this domain, severely reduces the binding to parkin. Consequently, the recruitment of parkin to mitochondria is inefficient. Both the FBXO7 R378G and R498X mutations had little or no effect on the interaction (Burchell et al. 2013) . Further findings of the study included that FBXO7 also binds to PINK1, whose binding is unaffected by the FBXO7 mutations and that PINK1 mediates the recruitment of FBXO7 to mitochondria. PINK1, parkin and FBXO7 act in concert to control the events leading to mitophagy. Among those events is, e.g., parkin-mediated ubiquitination of mitofusins that lead to the proteasomal degradation (Gegg et al. 2010; Tanaka et al. 2010) .
Interestingly, the expression of human FBXO7 in a parkin mutant fly model rescues its phenotype, which is characterized by, e.g. mitochondrial disruption and locomotor defects. Of note, none of the FBXO7 mutations, T22M, R378G, or R498X, is able to rescue the defects (Burchell et al. 2013 ). Burchell and colleagues also addressed whether loss of FBXO7 in flies has a similar phenotype as compared to parkin and examined ntc (nutcracker) mutant flies. Ntc was suggested to be the fly ortholog of mammalian FBXO7 (Bader et al. 2011) . Ntc flies, however, do not phenocopy any of the defects found in parkin flies but display male sterility (Bader et al. 2011) and show no disruption of mitochondria or flight ability, and no dopaminergic neurodegeneration (Burchell et al. 2013) . The expression of human FBXO7 does not reverse sterility, raising some doubts if ntc and FBXO7 are indeed orthologs (Burchell et al. 2013) . In contrast to parkin flies, the expression of human FBXO7 does not compensate for the loss of PINK1, which triggers similar defects as described for parkin mutant flies (Burchell et al. 2013) , revealing PINK1 as the critical upstream component of the PINK1/parkin/FBXO7 complex. Interestingly, ribonucleic acid interference (RNAi)-mediated reduction in the potential FBXO7 ortholog ntc in dopaminergic neurons of the fly leads to decreased lifespan and locomotor defects determined by a climbing assay. The latter, however, was shown in an a-synuclein-expressing fly and makes it rather hard to judge to what extent ntc RNAi alone triggers climbing defects, since ntc RNAi may act as a "second hit" and hence exacerbate an existing phenotype (Merzetti et al. 2017) .
Further investigations of FBXO7 loss-of-function on mitochondrial metabolism revealed reduced membrane potential (Dwm) and ATP levels in both a stable FBXO7 knockdown SH-SY5Y cells and in a fibroblasts derived from a Parkinsonian-pyramidal syndrome patient carrying the R378G mutation (Delgado-Camprubi et al. 2017). The authors further found that FBXO7 deficient cells display a reduced complex I-driven respiration together with altered NADH dehydrogenase activity and a reduced NAD+ pool, underscoring the importance of FBXO7 in mitochondrial function. Fig. 1 F-box protein O-type7 (FBXO7) acts at the proteasome and at dysfunctional mitochondria: On the one hand, the schematic shows the association of the E3 ligase FBXO7-SCF with the proteasome holoenzyme, which consists of the core particle and regulatory particles. Here, FBXO7 binds directly to a-subunit proteasomal subunit A2 (PSMA2), which is required for a fully functional and active proteasome. On the other hand, FBXO7 binds to PTEN-induced putative kinase 1 (PINK1) and parkin at the outer membrane to initiate mitophagy of dysfunctional mitochondria, which fail to produce ATP. Proteasomes and mitochondria are crucially important to cells and highly dependent on each other's functions and integrity. E2: E2-ubiquitin-conjugating enzyme; FBXO7: F-box protein only 7; PINK1: PTEN-induced putative kinase 1; PSMA2: proteasomal subunit a2; RBX1: RING-box protein 1; SCF: SKP1-cullin1-F-box; SKP1: S-phase kinase-associated protein 1; Ub: ubiquitin; K63: lysine 63-linked ubiquitination.
According to a recent biochemical study, FBXO7 has likely additional functions at mitochondria other than the recruitment of parkin. Teixeira and colleagues identified the mitochondrial protein translocase of outer mitochondrial membrane 20 (TOM20) in a ubiquitination target screen and validated TOM20 as a bona fide substrate of FBXO7 (Teixeira et al. 2016) . The authors reported ubiquitin modification of TOM20 by FBXO7 (Teixeira et al. 2016 ), but TOM20 also responds to the presence of the E3 ligase parkin upon CCCP treatment (Chan et al. 2011) . While FBXO7-mediated ubiquitination appears to have a stabilizing, nonproteolytic effects on TOM20 (Teixeira et al. 2016) , parkin promotes the proteasomefacilitated turnover of TOM20 prior to mitophagy (Chan et al. 2011) . To date it remains to be uncovered what the ubiquitination of TOM20 by FBXO7 means given that PARK15 mutations do not seem to affect this process (Teixeira et al. 2016) , and given that parkin recruitment sweeps TOM20 away from mitochondria (Chan et al. 2011) . In summary, the interaction of the PINK1/FBXO7/ parkin with the TOM complex (Lazarou et al. 2012) bears the trigger to complete mitophagy.
A recent study by Zhou and colleagues shed more light on FBXO7 and in particular on FBXO7 mutants in mitochondrial function. In contrast to the cytoplasmic localization of endogenous FBXO7 in neurons and in the brain, they reported the predominant nuclear localization of green fluorescent protein-tagged FBXO7 in cells (Zhou et al. 2015; Vingill et al. 2016) . The interesting observation, however, was that over-expressed wild-type FBXO7 tends to aggregate and that over-expression of FBXO7 mutants aggregate to a much larger extent, all of which are mostly cytoplasmic (Zhou et al. 2015) . They found that exposure to stress including exposure to dopamine and H 2 O 2 exacerbates the aggregation of FBXO7 mutants that partially localize to mitochondria as does wild type FBXO7. In addition, they showed that FBXO7 mutations affect the integrity of mitochondria, which is reflected in an increase in reactive oxygen species levels (Zhou et al. 2015) . Lastly, they demonstrated that FBXO7 promotes mitophagy supporting the findings by Burchell et al., but mutant versions of FBXO7 fail to stimulate this process (Burchell et al. 2013; Zhou et al. 2015) . Taken together, these studies establish an important role for FBXO7 in mitochondrial quality control and mutations of FBXO7 interfere with this function. The finding that FBXO7 is prone to aggregation and that FBXO7 aggregates can be detected in brains of PD patients is also an interesting piece of information as it is highly reminiscent of the aggregation-induced pathology of a-synuclein (Kalia et al. 2013; Lashuel et al. 2013; Zhao et al. 2013; Zhou et al. 2015) . Whether or not FBXO7 aggregates trigger the pathology in vivo remains to be elucidated. An interesting relationship of FBXO7 and a-synuclein was revealed in a recent report that presented the novel a-synuclein G51D mutation that co-segregates with Parkinsonian-pyramidal syndrome (Lesage et al. 2013) , indicating a genetic parkinsonism spectrum.
FBXO7 and proteasomal malfunctioning in PD
Proper proteasome function is fundamental for neuronal health and heavily dependent on ATP supplies. The proteasome, a large barrel-like multi-protein complex, consists of a 20S core particle that harbors proteolytic activity and one to two 19S regulatory particles (RP) that are required for the recognition of substrates, removal of ubiquitin chains and the proper unfolding and feeding of the protein into the core (Forster et al. 2013; Tomko and Hochstrasser 2013) . The core particle consists of two b-rings that are sandwiched in between two a-rings. Each ring consists of seven subunits. a-rings provide structural stability to the holoenzyme and interact with the RP, whereas b-rings harbor proteolytic activity (Dikic 2017) . In essence, the proteasome is essential for the degradation of worn out and unwanted proteins and hence a crucial regulator of protein homeostasis in cells.
The UPS has been implicated in PD for a long time ever since Lewy bodies have been described as ubiquitin-laden protein deposits Lowe et al. 1988) . Also, the selective decrease in proteasome activity and the reduction in proteasome subunits in the substantia nigra was observed in postmortem brains of PD patients (McNaught et al. 2002 (McNaught et al. , 2003 .
Proteasome function has been shown to be inhibited by several pesticides (Wang et al. 2006) , which is a validating finding of epidemiological studies that showed the association between parkinsonism and exposure to environmental toxins (Gorell et al. 1998; Di Monte et al. 2002) . The identified pesticides affect the activity of the 26S proteasome holoenzyme (Wang et al. 2006) , among those rotenone, a toxin previously used to model parkinsonism in mice (Betarbet et al. 2000) .
The devastating effects of proteasome activity deprivation have been impressively shown in a mouse genetics model in which proteasome function was specifically shut down in neurons of the substantia nigra and the forebrain by knocking out PSMC1, encoding the regulatory particle protein proteasomal subunit C1 (Bedford et al. 2008) . These conditional knockout mice displayed a rapid demise of neurons and a Lewy body-like pathology in the brain. Even a-synuclein, which is not part of the UPS, has the ability to meddle with UPS function (Snyder et al. 2003; Emmanouilidou et al. 2010) . Aggregated a-synuclein interacts with the 19S proteasome subunit, blocking protein interactions with the catalytic subunit, and obstructing 26S proteasome function. Interestingly, the E3 ligase parkin was also shown to associate with subunits of core and regulatory particle, which regulates proteasome function and assembly, and even links proteasomal activity to the clearance of proteins for mitophagy (Sakata et al. 2003; Dachsel et al. 2005; Um et al. 2010; Aguileta et al. 2015) . Um and colleagues could show that over-expression of wild-type parkin and to a lesser extent parkin mutants K161N and T240R stimulate proteasome activity by measuring the proteolysis of a reporter substrate (ubiquitin G76V-green fluorescent protein). In contrast, parkin R42P fails to stimulate the proteolysis of the reporter, which reveals the N-terminal region of parkin as critical in proteasome regulation. Consequently, the R42P mutant affects the binding of parkin to the proteasome (Sakata et al. 2003) .
A first hint that FBXO7 might have a regulatory role in proteasome function and activity was given when FBXO7 was reported to bind to PI31 (Kirk et al. 2008) . While PI31 appears to have inhibitory effects on proteasome function in vitro (Zaiss et al. 1999; Bader et al. 2011) , several studies support the view that PI31 has little or no effect on proteasome activity in vivo (Zaiss et al. 2002; Li et al. 2014; Vingill et al. 2016) , and potentially acts as a modulator of proteasome formation.
Putting the PI31 link aside, there was emerging evidence that FBXO7 plays a role in proteasome function. Mass spectrometry analyses examining the composition of isolated proteasomes identified FBXO7 as an associating protein (Bousquet-Dubouch et al. 2009; Fabre et al. 2015) , but left this finding uncommented. Our recent study independently revealed a direct interaction of FBXO7 with the core subunit PSMA2 and additionally showed the association of the FBXO7-SCF complex with the proteasome holoenzyme (Vingill et al. 2016) , Fig. 1 . Knockdown as well as loss-of-function analyses further demonstrated that FBXO7 regulates proteasome activity. While FBXO7 does not seem to affect the gating properties of the proteasome, it regulates the assembly of the core particle and regulatory particle of the proteasome and hence proper proteasomal activity (Vingill et al. 2016) . FBXO7 ubiquitinates PSMA2 in nonproteolytic manner, mostly by lysine 63-linkage. Unchanged PSMA2 protein levels in the FBXO7 knockout brain underscored the absence of proteolysis (Vingill et al. 2016) und suggests a functional modification that may support the successful assembly of core and regulatory particle or the integrity of the assembled proteasome. As to how FBXO7 mutations disrupt proteasome assembly and function remains to be established. It is also unclear if FBXO7 engages in an interaction with parkin at the proteasome, or if these molecules independently regulate proteasomal activity.
PARK15 mouse models
In general, the identification of PARK genes offers the opportunity to generate modified mouse lines by copying the pathological genetic situation found in humans. Mouse lines provide the means to monitor and examine the pathological events leading to PD and they allow for drug testing and the development of new therapies. The concept of generating humanized mouse models has been proven to pan out well for only a few mouse lines, such as the one expressing mutant parkin (Q311X). These animals display age-dependent characteristics of PD pathology such as neurodegeneration and motor deficits (Lu et al. 2009 ). To date, however, there is no mouse line, which faithfully recapitulates all pathological aspects and the course of PD (summary of current genetic models reviewed in: Jagmag et al. 2015) . Although several mouse models have been generated, there is a lot of variation when it comes to hallmark features of the disease such as the integrity of dopaminergic neurons or the degree of motor deficits (reviewed in: Blesa and Przedborski 2014; Shulman et al. 2011; Dawson et al. 2010) . Despite the imperfections, these mouse models are invaluable for the analyses of certain aspects of PD. Understanding, e.g., the early symptoms, intrinsic adaptation of neurons and the circuitry prior to onset of motor defects as well as the late-stage pathology is key to identifying new drug targets to enhance the survival of neurons.
As to how FBXO7 had the potential to enhance our understanding of parkinsonism was unpredictable at the time we launched our genetic approach. As described in the previous paragraphs, mutations in FBXO7 protein bring about loss-of-function (LOF) effects. FBXO7 mutants are more unstable than wild type and do not support FBXO7 0 s function in mitophagy (Burchell et al. 2013; Zhou et al. 2015) . The LOF effects are also supported by the absence of FBXO7 isoforms 1 and 2 in lymphoblastoid cells derived from an Italian PARK15 patient with the R498X mutation (Zhao et al. 2011) . In addition, Dutch PARK15 patients, carrying a compound mutation (T22M; IVS7+1G/T splice site), displayed absence of FBXO7 isoform 1 and reduced amounts of isoform 2 in skin fibroblast and lymphoblastoid cells (Zhao et al. 2011) . A knockout strategy to determine the relevance of FBXO7 in the organism and in particular in neurons seemed appropriate. The systemic deletion of FBXO7 in mice is characterized by a strong phenotype that includes motor defects and premature death (Vingill et al. 2016) , supporting the LOF view. This is in stark contrast to, e.g., parkin knockout mice, which show little or no effect on viability and on central nervous system development (Goldberg et al. 2003) , suggesting that while parkin is largely dispensable for proper development, FBXO7 is critically required for both development and survival of the mouse. Hence, a mitophagy deficit may not be the main reason as to why FBXO7-/-mice die prematurely. An accumulation of defects including those in proteasome function is more likely.
Reduced proteasome activity in the brain of FBXO7 knockout mice is consistent with its biochemical role at the proteasome (Vingill et al. 2016) . This finding also supports the notion that proteolytic stress has previously been viewed as a crucial factor contributing to parkinsonism. Attempts so far to successfully establish a reliable parkinsonism animal model induced by the systemic exposure to proteasome inhibitors failed. While one study showed a motor phenotype together with dopaminergic cell death (McNaught et al. 2004) , the other study following the very same protocol was unable to reproduce these findings (Bove et al. 2006) . Genetic models such as the FBXO7 mouse models might be more reliable to expose neurons to chronic proteolytic stress and thus to induce functional deficits and slow wasting of those neuronal populations, which are most vulnerable to insufficient proteasome activity. As of now, however, we cannot tell if the proteasomal deficit is the main effector pathway or if all FBXO7-controlled pathways contribute equally to the phenotype of the mouse.
Owing to the short life span of the FBXO7 knockout mice, conditional mouse lines harboring FBXO7 deletions in either the forebrain to examine pyramidal motor deficits, or in TH+ neurons to investigate extrapyramidal motor deficits, were generated in a parallel approach. The conditional deletion of FBXO7 in forebrain results in early-onset motor defects in 2-month-old mice (Vingill et al. 2016 ). This could be translated into the pyramidal signs observed in PARK15 patients. Without any obvious cell death of FBXO7-/-glutamatergic neurons or a-synuclein-positive deposits at the time of analyses (Vingill et al. 2016) , loss of FBXO7 may trigger morphological, or connectivity defects in neurons. Later analyses to determine neuronal survival in the cortex are not possible because of humane end point criteria necessitated by the severe motor phenotype at 4 months of age.
Deletion of FBXO7 in tyrosine hydroxylase-expressing neurons results in late-onset motor defects, which are reflected in mild motor coordination problems in 6 monthold mice when challenged on the rotarod only (Vingill et al. 2016) . Any differences in the gait of the conditional knockout out mice are indistinguishable by eye, but Digigait TM , which facilitates computer-assisted analyses of the gait, revealed significant differences. The system, highly sensitive to subtle changes, showed that parameters altered include reduced paw area and width of the footprints, reduced stride duration and length, reduced stance and propulsion, as well as less rapid deceleration (Vingill et al. 2016) . Many of these parameters are Digigait TM -established changes of the gait in the neurotoxin MPTP PD mouse model (Amende et al. 2005) .
Interestingly, the conditional deletion of FBXO7 in TH+ neurons leads to a 50% reduction in striatal dopamine at 2 months of age when there are no motor deficits detectable. While deletion of FBXO7 in TH+ neurons does not induce major cell loss or accumulation of a-synuclein-positive deposits, it induces a chronic reduction in striatal dopamine that accumulates to severe motor problems in 12-month-old mice (Vingill et al. 2016) .
The conditional deletion of FBXO7 in neurons may be subject to criticism, as this does not reflect the pathological genetic situation in humans. The analyses thus far are, however, promising and allow for a detailed examination of events that are induced by chronic dopamine reduction, which is very well a situation that triggers the early stages of PD. In future analyses, the generation of humanized FBXO7 mouse models expressing the pathogenic mutants maybe useful tools as well, as they might recapitulate a similar phenotype and allow for further novel insight.
Conclusion
Although PARK15 is such a rare disorder with only a handful of families described so far, research over the past few years revealed FBXO7 as an important player in two major pathways that are central in the pathology of PD/ parkinsonism (Fig. 1) . Genetic mutations bring susceptible pathways to light and allow us to understand what goes awry in PD. To search for a cure, knowing the components of the pathways is a crucial foundation. Not only will the knowledge of the pathways unravel the complexity of the disease and spark important new ideas of how to therapeutically alleviate the disease, it will also give hope to an ever growing population of PD patients.
